Effect of corticosteroids on atrial fibrillation after catheter ablation: a meta-analysis.
- Author:
Sanjay JAISWAL
1
;
Xian-Bao LIU
1
;
Qu-Cheng WEI
1
;
Ying-Hao SUN
1
;
Li-Han WANG
1
;
Liu-Guang SONG
1
;
Dan-Dan YANG
1
;
Jian-An WANG
1
Author Information
- Publication Type:Meta-Analysis
- Keywords: Atrial fibrillation; Corticosteroids; Catheter ablation; Meta-analysis
- MeSH: Adrenal Cortex Hormones/therapeutic use*; Aged; Atrial Fibrillation/drug therapy*; Catheter Ablation/adverse effects*; Cohort Studies; Humans; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Treatment Outcome
- From: Journal of Zhejiang University. Science. B 2018;19(1):57-64
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:The purpose of this meta-analysis was to explore the effect of corticosteroids on atrial fibrillation (AF) following catheter ablation.
METHODS:We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for published articles describing the effect of corticosteroids in preventing AF recurrence after catheter ablation. Data on study and patient were extracted. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated by use of a random-effect model, and P values of <0.05 were considered significant.
RESULTS:Two randomized controlled trials (RCTs) and three cohort studies involving 846 patients were included in this meta-analysis. Within one month of catheter ablation, corticosteroid use was associated with a declined risk of recurrence of AF in RCT (RR 0.57, 95% CI 0.39 to 0.85, P=0.005), but without significant effect in cohort studies (RR 1.01, 95% CI 0.79 to 1.30, P=0.94). After three months of catheter ablation, corticosteroids did not have a significant effect in the prevention of late recurrence of AF in either RCT (RR 0.78, 95% CI 0.38 to 1.59, P=0.49) or cohort studies (RR 0.96, 95% CI 0.70 to 1.31, P=0.78).
CONCLUSIONS:Our meta-analysis suggested that periprocedural administration of corticosteroids of catheter ablation was associated with reduction of early but not late recurrence of AF.
